文献速递急性肾损伤慢性肾脏病遗传性与小管间质肾病

特发性腹膜后纤维化:肾内科医生更新要点

Idiopathic retroperitoneal fibrosis: an update for nephrologists.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

特发性腹膜后纤维化(IRF)是一种以主动脉周围和髂部周围组织慢性炎症浸润和显著纤维化为特征的罕见疾病,可导致输尿管梗阻性肾病,引起急性肾衰竭和慢性肾脏病。IRF可能孤立发生或与自身免疫病相关,遗传变异(如HLA-DRB1*03)和环境因素(石棉暴露和吸烟)增加风险,趋化因子和细胞因子网络参与炎症和纤维化。糖皮质激素单用或联合免疫抑制剂通常有效,但高达50%患者复发,生物制剂如利妥昔单抗正在探索中,介入操作(如输尿管支架)可解除梗阻,手术输尿管松解术用于难治性病例,总体和肾脏预后良好,<5%患者进展至终末期肾病。

要点

  • IRF是免疫介导的罕见病,可导致输尿管梗阻和肾功能损害。
  • 糖皮质激素联合免疫抑制剂是一线治疗,但高达50%患者复发。
  • 利妥昔单抗等生物制剂正在探索用于IRF治疗。

核心结论

  • IRF是一种免疫介导的潜在系统性纤维炎性疾病,可导致梗阻性肾病和慢性肾脏病。
  • 糖皮质激素单用或联合传统免疫抑制剂通常有效,但高达50%患者复发。
  • 生物制剂如利妥昔单抗正在探索中,介入操作如输尿管支架可解除梗阻。

研究设计与样本

  • 综述,未报告系统检索范围。

主要发现

  • 遗传变异如HLA-DRB1*03和环境因素如石棉暴露和吸烟与IRF风险增加相关。
  • 趋化因子如CXCL12和CCL11及细胞因子如IL-6、IL-12和IL-13可能协调炎症反应并促进纤维化。
  • 高达50%患者复发,需要重复免疫抑制治疗;<5%患者进展至终末期肾病。

临床怎么用

  • 肾内科医生应识别IRF的梗阻性肾病表现,及时解除输尿管梗阻。
  • 糖皮质激素单用或联合甲氨蝶呤或吗替麦考酚酯是常用治疗方案。
  • 对复发患者可考虑重复免疫抑制疗程或探索生物制剂如利妥昔单抗。
  • 手术输尿管松解术一般保留用于难治性病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Idiopathic retroperitoneal fibrosis (IRF) is a rare condition characterized by the development of a peri-aortic and peri-iliac tissue showing chronic inflammatory infiltrates and pronounced fibrosis. Ureteral entrapment with consequent obstructive uropathy is one of the most common complications of IRF, which can lead to acute renal failure and, in the long term, to varying degrees of chronic kidney disease. IRF may be isolated or develop in association with autoimmune diseases (e.g. Hashimoto's thyroiditis and psoriasis) and other fibro-inflammatory disorders (often within the spectrum of immunoglobulin G4-related disease), which suggests that it should be considered as a potentially systemic condition. IRF is an immune-mediated disease: genetic variants (e.g. human leukocyte antigen (HLA)-DRB1*03) and environmental agents (mainly exposure to asbestos and smoking) are strongly associated with an increased risk of developing the disease, while a complex network of chemokines (e.g. CXCL12 and C-C moti chemokine 11 (CCL11)) and cytokines [e.g. interleukin (IL)-6, IL-12 and IL-13] is likely to orchestrate the inflammatory response and simultaneously promote fibrosis. Glucocorticoids, alone or in combination with traditional immunosuppressants such as methotrexate and mycophenolate mofetil, are usually efficacious and promptly induce disease remission; however, up to 50% of patients relapse, thus requiring repeat immunosuppressive courses. Biologic drugs, namely rituximab, are being explored for the treatment of IRF. In addition to medical therapies, interventional procedures (mainly ureteral stenting) are required to relieve ureteral obstruction, whereas surgical ureterolysis is generally reserved to refractory cases. If appropriately treated, then the overall and renal prognosis of IRF are good, with <5% patients developing end-stage renal disease.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Raglianti V, Rossi GM, Vaglio A, et al. Idiopathic retroperitoneal fibrosis: an update for nephrologists. Nephrol Dial Transplant. 2021. PMID: 33005943. doi:10.1093/ndt/gfaa083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。